argenx NV ADR (ARGX)vsCelularity Inc (CELU)
ARGX
argenx NV ADR
$1,023.21
-3.37%
HEALTHCARE · Cap: $64.66B
CELU
Celularity Inc
$1.58
-24.76%
HEALTHCARE · Cap: $21.32M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 19921% more annual revenue ($5.32B vs $26.55M). ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 71/100 (B).
ARGX
Strong Buy71
out of 100
Grade: B
CELU
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.2%
Fair Value
$2398.58
Current Price
$1023.21
$1375.37 discount
Margin of Safety
+72.5%
Fair Value
$4.47
Current Price
$1.58
$2.89 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 190.2x book value
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -6367.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : CELU
The strongest argument for CELU centers on Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CELU is a value play — different risk/reward profiles.
CELU carries more volatility with a beta of 0.54 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (71/100 vs 21/100), backed by strong 32.3% margins and 59.3% revenue growth. CELU offers better value entry with a 72.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. The company is advancing a promising pipeline of allogeneic immunotherapies aimed at enhancing treatment outcomes for cancer patients and those with severe medical conditions, while reducing associated complications. With a strong leadership team and strategic partnerships, Celularity is positioned to become a significant force in the dynamic advanced therapeutics sector, addressing critical unmet medical needs and driving advancements in patient care.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?